NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $7.26 -0.07 (-0.95%) (As of 10/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AUPH alerts:Sign Up Key Stats Today's Range$7.11▼$7.3450-Day Range$5.32▼$7.3352-Week Range$4.71▼$10.05Volume871,187 shsAverage Volume1.69 million shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company OverviewAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Read More… Retire off just one stock ticker? (Ad)ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...Click here for the ticker >>> Aurinia Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks69th Percentile Overall ScoreAUPH MarketRank™: Aurinia Pharmaceuticals scored higher than 69% of companies evaluated by MarketBeat, and ranked 348th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth246.15% Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow by 246.15% in the coming year, from $0.13 to $0.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -16.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -16.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aurinia Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.31% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 12.97%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.31% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 12.97%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.21 News SentimentAurinia Pharmaceuticals has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest34 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 386% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $96,902.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Stock News HeadlinesAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest UpdateSeptember 29 at 2:45 PM | americanbankingnews.comAurinia Pharmaceuticals: Strategic Growth and Buy Rating Amidst Japan Market Expansion and M&A PotentialSeptember 27, 2024 | markets.businessinsider.comGet Ready for Next Week’s Elon Musk Shock I believe Elon Musk is about to shock the world again next week… When he’s set to unveil his new AI product. I’m hosting a special online strategy session to help you prepare on Monday at 10am ET.October 2, 2024 | InvestorPlace (Ad)Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From ProfitabilitySeptember 27, 2024 | finance.yahoo.comAurinia Announces Japan Approval of LUPKYNIS ® (Voclosporin) to Treat Lupus NephritisSeptember 26, 2024 | businesswire.comAurinia Pharma Gets Approval in Japan for Lupus TreatmentSeptember 24, 2024 | marketwatch.comAurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus NephritisSeptember 24, 2024 | stockhouse.comAurinia Announces Approval Of LUPKYNIS In Japan - Quick FactsSeptember 24, 2024 | markets.businessinsider.comSee More Headlines AUPH Stock Analysis - Frequently Asked Questions How have AUPH shares performed this year? Aurinia Pharmaceuticals' stock was trading at $8.99 at the beginning of the year. Since then, AUPH stock has decreased by 19.2% and is now trading at $7.26. View the best growth stocks for 2024 here. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. Aurinia Pharmaceuticals's quarterly revenue was up 37.6% compared to the same quarter last year. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA) and Exelixis (EXEL). Company Calendar Last Earnings8/01/2024Today10/01/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AUPH CUSIPN/A CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$13.00 Low Stock Price Target$8.00 Potential Upside/Downside+37.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E Ratio55.85 P/E GrowthN/ANet Income$-78,020,000.00 Net Margins-24.31% Pretax Margin-23.22% Return on Equity-11.84% Return on Assets-8.25% Debt Debt-to-Equity Ratio0.18 Current Ratio5.33 Quick Ratio4.82 Sales & Book Value Annual Sales$207.11 million Price / Sales5.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book2.76Miscellaneous Outstanding Shares142,664,000Free Float136,529,000Market Cap$1.04 billion OptionableOptionable Beta1.44 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:AUPH) was last updated on 10/2/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredThey laughed when he picked Nvidia in 2016…Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.